Biogen expects 'minimal' revenue this year from its Alzheimer's treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.
The Biogen Inc., headquarters in Cambridge. Biogen released a surprisingly low 2022 forecast Thursday, Feb. 3, 2022, as the drugmaker deals with sluggish sales from an Alzheimer’s treatment initially hailed as a potential breakthrough drug.
Aduhelm entered the U.S. market after federal regulators approved it last June, but it received pushback from doctors and patient advocates over its initial price of more than $50,000 annually, not counting insurance coverage. The Centers for Medicare and Medicaid Services said in a preliminary coverage decision that patients taking Aduhelm will have to participate in another study that evaluates the drug's effectiveness in order for Medicare to cover the cost.
He said it also would duplicate what Biogen, which developed Aduhelm with Japan's Eisai Co., is already doing to collect more data on its drug.Aduhelm sales of $1 million in the fourth quarter remained"incredibly light," Mizuho Securities analyst Salim Syed said in a research note.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Biogen says U.S. FTC, SEC probing Alzheimer's disease drugThe U.S. Federal Trade Commission and the U.S. Securities and Exchange Commission have asked Biogen Inc to provide information on the approval and marketing of its new Alzheimer's disease treatment, Aduhelm, the drugmaker disclosed in a filing.
Les mer »
BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer's drugBiogen's new Alzheimer's drug aduhelm saw limited pickup in its first few months on the market.
Les mer »
5 Wellness Essentials Jamie Anderson Is Bringing to Beijing | Well+GoodOlympic snowboarder Jamie Anderson shares what she's packing in her bags to the 2022 Winter Olympics in Beijing.
Les mer »
BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer's drugBiogen's new Alzheimer's drug aduhelm saw limited pickup in its first few months on the market.
Les mer »
Facebook owner Meta loses record $232 billion in market value after 'saying the quiet part out loud'Meta’s 26% stock plunge Thursday shaved $232 billion off the company’s market value -- the largest single-day decline in market value on record for any U.S. company.
Les mer »
Toyota Tundra Capstone #001 sells for $700,000The first 2022 Toyota Tundra Capstone, with VIN 001 sells for $700,000 at Barrett-Jackson auctions, while a 2022 TRD Pro sells for $550,000, all for charity.
Les mer »